PF-3187207 (latanoprostene bunod) demonstrated potent ocular hypotensive effects in preclinical models. In primates with laser-induced ocular hypertension, topical administration of 0.036% and 0.12% latanoprostene bunod reduced intraocular pressure (IOP) by up to 31% and 35%, respectively, outperforming latanoprost 0.1%, which achieved a maximum 26% IOP reduction. The dual action involves prostaglandin-mediated enhancement of uveoscleral outflow and nitric oxide-induced relaxation of the trabecular meshwork, increasing aqueous humor outflow. This combined mechanism led to sustained and significant IOP lowering without notable adverse effects. These results support its potential as an effective treatment for glaucoma and ocular hypertension by improving aqueous humor drainage through complementary pathways.